title: Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): results from a pilot study.
abstract: There is no effective therapy available for stage D2 prostate cancer once patients become refractory to hormonal therapy. In a pilot study, we treated 17 patients with hormone-refractory stage D2 prostate cancer using autolymphocyte therapy, an outpatient form of adoptive immunotherapy in which patients are treated with autologous T cells that have been activated ex vivo. Feasibility and safety were documented. Transient PSA reductions up to 66% were noted, suggesting biological activity. Further studies to test the safety and efficacy of autolymphocyte therapy in the treatment of prostate cancer are warranted.
authors.affiliation: Joint Clinical Immunotherapy Program, Boston University School of Medicine, MA.
authors.forename: S
authors.initials: S
authors.lastname: Ross
authors.forename: V
authors.initials: V
authors.lastname: Liu
authors.forename: R
authors.initials: R
authors.lastname: Abulafia
authors.forename: C
authors.initials: C
authors.lastname: Hogan
authors.forename: M
authors.initials: M
authors.lastname: Osband
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002478:Cells, Cultured; D005240:Feasibility Studies; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010641:Phenotype; D010865:Pilot Projects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D017430:Prostate-Specific Antigen